Mounjaro Faces Intensifying Competition as HSBC Flags Eli Lilly Obesity Drug Market Risks

Eli Lilly's blockbuster diabetes drug Mounjaro drives massive revenue but grapples with off-label weight loss demand, pricing pressures, and rivals like Novo Nordisk's oral Wegovy gaining traction amid analyst downgrades.

Eli Lilly's Mounjaro, the tirzepatide-based injection for type 2 diabetes, hit a pivotal moment as HSBC downgraded the company's stock today, citing overoptimistic market projections for obesity treatments and looming pricing battles. This development underscores commercial pressures on Mounjaro's dual role in blood sugar control and weight management, where off-label use fuels growth but invites regulatory and competitive scrutiny. For DACH investors, it signals caution on Eli Lilly shares amid Europe's tightening reimbursement rules for high-cost GLP-1 drugs.

As of: 18.03.2026

Dr. Elena Voss, Senior Pharma Analyst: Mounjaro exemplifies how diabetes therapies are reshaping weight loss markets, but sustainability hinges on navigating competition and access barriers in Europe.

Mounjaro's Core Mechanism and Recent Momentum

Mounjaro operates as a dual GIP and GLP-1 receptor agonist, mimicking hormones that regulate blood sugar, appetite, and insulin sensitivity. Administered weekly via injection at doses from 2.5mg to 15mg, it delivers superior glycemic control compared to single-agonist rivals.

Recent data shows average weight reductions of 15-20% in diabetes patients, driving off-label prescriptions despite its FDA approval strictly for type 2 diabetes—not obesity. This distinction matters: Zepbound, its sister brand with identical tirzepatide, holds obesity approval, splitting insurance pathways.

Supply constraints have eased, but demand surges from social media trends and celebrity endorsements keep utilization high. Monthly self-pay costs exceed $1,300, limiting access without coverage.

In Europe, EMA nods focus on diabetes, with weight loss benefits acknowledged but not primary. German funds like AOK reimburse selectively for BMI over 30 or comorbidities.

HSBC Downgrade Signals Market Headwinds

HSBC slashed Eli Lilly's price target from $1,070 to $850, arguing Wall Street overestimates the obesity market at $150 billion plus. Their forecast caps it at $80-120 billion by 2032, pressured by pricing erosion.

Lilly's CFO Lucas Montarce countered, emphasizing orforglipron's oral convenience. Yet Novo Nordisk's oral Wegovy hit 50,000 weekly prescriptions rapidly, stealing share from injectables like Mounjaro.

For Mounjaro, this intensifies scrutiny: diabetes sales boom, but weight loss cannibalization risks arise as patients switch to approved obesity options or cheaper generics loom post-patent.

Europe amplifies this, with G-BA assessments capping GLP-1 prices amid budget strains. DACH payers demand long-term data beyond glycemic endpoints.

Clinical Profile and Patient Eligibility

Patients qualify with BMI ?30 or ?27 plus conditions like hypertension or sleep apnea. Gastrointestinal side effects—nausea, diarrhea—peak during dose escalation but wane.

Contraindicated in pregnancy, Mounjaro demands monitoring for gallbladder risks. Long-term trials show cardiovascular benefits, bolstering case for broader use.

In DACH, real-world evidence from RWE registries supports efficacy in obese diabetics, but adherence drops with injection fatigue. Oral shifts threaten retention.

Tirzepatide's dual action outperforms semaglutide in head-to-heads, with faster weight loss onset. Yet daily rivals like Victoza offer alternatives for tolerability-focused patients.

Commercial Stakes in Weight Loss Boom

Mounjaro powers Lilly's revenue, contributing billions quarterly as diabetes overlaps obesity epidemics. Off-label momentum sustains growth despite Zepbound ramp-up.

Pricing dynamics drive margins, but HSBC warns of erosion as volumes peak. Novo competition accelerates this, with Wegovy's oral form easing adherence barriers.

Global supply chains stabilize, yet Europe faces import delays. DACH demand swells via private clinics, bypassing public waits.

Pipeline expansions target combos, but execution risks mount. Investors eye Q1 earnings for tirzepatide uptake metrics.

Investor Context: Eli Lilly Shares Under Pressure

ISIN US5324571083 tracks Eli Lilly common stock, up over 1,500% decade-to-date on GLP-1 success. Today's HSBC note tempers enthusiasm, projecting moderated growth.

DACH funds hold significant positions, drawn to dividend yield and pipeline. Volatility spikes on FDA orforglipron news, expected April 2026.

Risk-reward tilts defensive: strong cashflow offsets market cap debates. Monitor reimbursement shifts in Germany, Austria, Switzerland.

European Reimbursement and Access Challenges

In Germany, Mounjaro gains traction under diabetes codes, but weight-only claims face denial. Swiss funds prioritize CVD risk reducers.

Austrian HTA reviews emphasize cost-effectiveness, capping budgets. Private pay thrives in wellness clinics catering Abnehm-Trend.

Cross-border arbitrage emerges, with patients sourcing from low-regulation markets. Regulators eye safety amid social media hype.

Future Outlook: Orals vs Injectables

Orforglipron could eclipse Mounjaro if approved, offering pill simplicity. Early data rivals injections on efficacy.

Novo's lead pressures Lilly to differentiate via combos or indications. Sleep apnea nod for Zepbound hints expansions.

DACH investors watch EMA label updates, pricing negotiations. Long-term, market fragmentation favors innovators.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.